Sepsis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The sepsis therapeutics market is projected to register a CAGR of 7.6% over the forecast period. The major factor attributing to the growth of the market is the rising incidence of sepsis globally. According to the World Health Organization, it is estimated to affect more than 30 million people worldwide every year, potentially leading to 6 million deaths. The burden of sepsis is most likely the highest in the low- and middle-income countries. Furthermore, increasing research and development programs and funding are the factors boosting the market's growth.

However, the lack of initial diagnostic test for identifying sepsis conditions and the lack of awareness about the treatment are the factors constraining the market's growth.

Key Market Trends

Cephalosporins Dominate the Sepsis Therapeutics Market

The dominant share of the segment is attributed to the vast usage of the drug class, individually or in combination with the other drugs.

Cephalosporins are divided into the first, second, third, and fourth generation. First-generation cephalosporins have greater activity against gram-positive bacteria. The succeeding generations have increased activity against gram-negative bacteria and decreased activity against gram-positive bacteria.

Apart from the advantages and broad-spectrum activity of cephalosporins, the increasing incidence of sepsis is expected to boost the segment's growth.

North America Dominates the Market and Expected to do Same in the Forecast PeriodNorth America is expected to dominate the overall sepsis therapeutics market, throughout the forecast period. The largest share is mainly due to presence of larger patient pool and increasing geriatric population. Furthermore, well-established insurance policies and the availability of advanced healthcare infrastructure are few of the other factors boosting the market in this region. In North America region, the United States holds the largest market share due to the factors such as increasing number of geriatric populations, along with a growing number of patient pool in the country. According to Sepsis.org., more than 1.7 million people in the country are diagnosed with sepsis each year, one every 20 seconds and the incidence is rising 8% every year and the cost of hospitalization in the U.S. consuming more than USD 27 billion each year. As per the statistics the large patient pool and high disposable income propels the market growth in the region.

North America is expected to dominate the overall sepsis therapeutics market, throughout the forecast period. The largest share is mainly due to the presence of larger patient pool and increasing geriatric population. Furthermore, well-established insurance policies and the availability of advanced healthcare infrastructure are few of the other factors boosting the market in this region. In North America region, the United States holds the largest market share due to the factors such as increasing number of geriatric populations, along with a growing number of patient pool in the country. According to Sepsis.org., more than 1.7 million people in the country are diagnosed with sepsis each year, one every 20 seconds and the incidence is rising 8% every year and the cost of hospitalization in the U.S. consuming more than USD 27 billion each year. As per the statistics the large patient pool and high disposable income propels the market growth in the region.

Competitive Landscape

The sepsis therapeutics market is moderately competitive. A few of the crucial approaches followed by players are product development, invention, acquisitions, and mergers. Some of the companies currently dominating the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline Inc., Mylan NV, and Allergan Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support